| Literature DB >> 31624274 |
R Chandirasekar1, K Murugan2,3, T Muralisankar2, V Uthayakumar4, R Jayakumar5, K Mohan4,6, C Vasugi4, R Mathivanan4, S Mekala4, A Jagateesh7, K Suresh2.
Abstract
Smoking and smokeless tobacco consumption is a significant risk factor that provokes genetic alterations. The present investigation was to evaluate the biomarkers of genotoxicity including micronucleus (MN), chromosome aberrations (CA) and DNA strand breaks among tobacco consumers and control individuals residing in hilly areas of Western Ghats, Tamilnadu, South India. This study included 268 tobacco consumers with equal number of controls. The tobacco consumers were divided into Group I (<10 years of tobacco consumption with an age range from 15 to 35 years) and group II (>10 years consumption above 35 years of age). Chromosome aberration (CA) and comet assay were performed using blood and micronucleus assay from exfoliated buccal epithelial cells obtained from tobacco consumers and controls. Elevated levels of CA were found in group II (Chromatid type: 2.39 ± 1.13 and chromosome type: 1.44 ± 1.24) exposed subjects, high micronucleus and DNA damage (TL:4.48 ± 1.24 and TM:3.40 ± 1.58) levels were significantly (p < 0.05) observed in both smoking and smokeless tobacco consumers when comparison with group I and controls. This study also observed a lack of awareness among the tobacco consumers about the harmful health effects of tobacco. Tobacco consumption contributes to the significant alteration in genetic materials. In addition, a high rate of spontaneous abortion was also seen in the studied population.Entities:
Mesh:
Year: 2019 PMID: 31624274 PMCID: PMC6797791 DOI: 10.1038/s41598-019-51275-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic details of age and year of exposure and risk factors in tobacco users.
| Particulars | No. of sample and % | Year of exposure | Age | BP (%) | Diabetes | Spontaneous Abortion | Cardiac Complaint |
|---|---|---|---|---|---|---|---|
|
| 268 | 11.74 ± 5.97 | 43.70 ± 15.78 | 36 (13.43) | 41 (15.30) | 16 (5.97) | 8 (2.98) |
| Male | 103 (38.43) | 12.74 ± 6.94 | 42.55 ± 16.23 | 17 (16.50) | 18 (17.47) | 6 (5.82) | |
| Female | 165 (61.56) | 11.11 ± 5.21 | 44.41 ± 15.50 | 19 (11.51) | 23 (13.93) | 16 (5.97) | 2 (1.21) |
|
| |||||||
| | 112 (41.79) | — | 32.08 ± 8.57 | — | 1 (0.97) | — | |
| Male | 39 (34.81) | — | 29.74 ± 6.79 | — | — | — | — |
| Female | 73 (65.17) | — | 33.34 ± 9.19 | — | 1 (1.36) | — | — |
| | 156 (58.20) | — | 53.33 ± 8.58 | 5 (3.20) | 5 (8.33) | — | — |
| Male | 64 (41.02) | — | 54.25 ± 9.32 | 3 (4.64) | 2 (3.12) | — | — |
| Female | 92 (58.97) | — | 52.70 ± 8.01 | 2 (2.17) | 3 (3.26) | — | — |
|
| — | ||||||
| | 112 (41.79) | 6.26 ± 1.86 | 30.31 ± 6.50 | 4 (3.57) | 8 (7.14) | — | — |
| Male | 39 (34.81) | 5.69 ± 2.02 | 27.80 ± 6.74 | 1 (2.56) | 3 (7.69) | — | |
| Female | 73 (65.17) | 6.57 ± 1.71 | 31.65 ± 5.98 | 3 (4.510) | 5 (6.84) | 16 (5.97) | — |
| | 156 (58.20) | 15.67 ± 4.67 | 53.54 ± 13.49 | 32 (20.51)* | 33 (21.15) | — | — |
| Male | 64 (41.02) | 17.04 ± 5.10 | 51.54 ± 13.49 | 16 (25.00) | 15 (23.43) | — | 6 (5.82) |
| Female | 92 (58.97) | 14.71 ± 4.11 | 54.54 ± 13.05 | 16 (17.39) | 18 (19.56) | — | 2 (1.21) |
|
| 268 | ||||||
| Smokers | 6 5(24.25) | 10.96 ± 6.99 | 35.78 ± 14.91 | 1(1.53) | 3(4.61) | — | |
| SL tobacco users | 154 (57.46) | 11.03 ± 5.31 | 41.96 ± 14.18 | 20 (12.98) | 22 (14.28) | 16 (5.97) | — |
| Smokers and SLT users | 49 (18.28) | 14.97 ± 5.51 | 59.65 ± 09.65 | 35 (71.42)* | 16(32.65) | 8 (2.98) | |
SD = standard deviation. FS: Female subjects, RR: Reference range. *Significantly higher when compared to the other groups.
Frequencies of micronuclei scored in buccal and blood cells of tobacco users and controls.
| Particulars | No. of subjects studied | Mean frequency of micronuclei ± standard deviation of MN scored in blood cells/1000 (mean ± SD) | Mean frequency of micronuclei ± standard deviation of MN scored in buccal cells/2000 (mean ± SD) | Blood | Buccal |
|---|---|---|---|---|---|
|
| |||||
| | 112 | 0.70 ± 0.65 | 0.76 ± 0.69 | ||
| Male | 39 | 0.82 ± 0.68 | 0.69 ± 0.61 | 0.002 | |
| Female | 73 | 0.64 ± 0.63 | 0.80 ± 0.73 | 0.031 | |
| | 156 | 1.16 ± 0.67 | 1.08 ± 0.82 | 0.003 | 0.45 |
| Male | 64 | 1.25 ± 0.69 | 1.03 ± 0.77 | ||
| Female | 92 | 1.10 ± 0.67 | 1.13 ± 0.85 | 0.001 | |
|
| |||||
| | 112 | 1.73 ± 0.90 | 2.19 ± 1.42 | 0.004 | |
| Male | 39 | 1.87 ± 0.76 | 2.46 ± 1.41 | 0.001 | |
| Female | 73 | 1.65 ± 0.96 | 2.05 ± 1.42 | 0.909 | |
| | 156 | 2.46 ± 0.88# | 3.01 ± 1.38* | 0.001 | |
| Male | 64 | 2.65 ± 0.82** | 2.96 ± 1.40 | 0.001 | 0.002 |
| Female | 92 | 2.32 ± 0.91 | 2.67 ± 1.46 | ||
|
| 268 | ||||
| Smokers | 65 | 2.12 ± 0.83 | 2.90 ± 1.55 | 0.001 | |
| SLT users | 154 | 2.02 ± 0.98 | 2.53 ± 1.34 | ||
| Smokers and SLT users | 49 | 2.61 ± 0.93a | 2.79 ± 1.64 | 0.001 | 0.001 |
*,#Significantly elevated when compared to controls subjects as estimated by ANOVA.
**Significantly elevated compared to controls and group I and female experimental subjects.
aSignificantly elevated compared to controls and smokers experimental subject as estimated by ANOVA followed by Bonferroni’s correction for multiple comparisons.
Figure 1(A) Represent the frequencies of micronuclei in buccal and blood cells of tobacco exposures and controls. Blood MN level was elevated when compared to the controls and other subjects. #indicates significantly higher when compared to female and other groups. (B) Shows the chromosome alterations in controls and experimental subjects. A super scribed (*) indicates the data is significance at p < 0.005 level when compared to other subjects. (C) Demonstration of comets scored in blood cells of tobacco users and controls. A super scribed (*) indicate the significance at p < 0.005 level when compared to other subjects.
Frequencies of chromosome aberrations in smokeless tobacco users and controls.
| Subjects | Number of samples | Chromosome aberrations | Chromatid- type aberrations | Chromosome-type aberration | |
|---|---|---|---|---|---|
| Chromatid- type aberrations (mean ± SD) | Chromosome-type aberration (mean ± SD) | ||||
|
| |||||
| | 112 | 0.71 ± 0.80 | 0.54 ± 0.51 | ||
| Male | 39 | 0.69 ± 0.79 | 0.53 ± 0.50 | ||
| Female | 73 | 0.76 ± 0.80 | 0.54 ± 0.52 | 0.324 | 1 |
| | 156 | 0.99 ± 0.71 | 0.76 ± 0.71 | ||
| Male | 64 | 1.01 ± 0.70 | 0.79 ± 0.80 | 0.052 | 0.912 |
| Female | 92 | 0.97 ± 0.72 | 0.73 ± 0.66 | 0.031 | |
|
| |||||
| | 112 | 1.68 ± 0.93 | 0.80 ± 0.75 | ||
| Male | 39 | 1.61 ± 0.96 | 0.76 ± 0.80 | 0.001 | |
| Female | 73 | 1.72 ± 0.91 | 0.82 ± 0.73 | 0.325 | |
| | 156 | 2.39 ± 1.13 | 1.44 ± 1.24 | 0.001 | |
| Male | 64 | 2.45 ± 1.19 | 1.51 ± 0.99 | 0.001 | 0.235 |
| Female | 92 | 2.30 ± 1.10 | 1.40 ± 1.39 | ||
|
| 268 | ||||
| Smokers | 65 | 1.93 ± 1.13 | 1.04 ± 0.94 | ||
| SLT users | 154 | 2.02 ± 1.04 | 1.12 ± 1.20 | ||
| Smokers and SLT users | 49 | 2.55 ± 1.19 | 1.53 ± 0.93*a | 0.001 | 0.001 |
*Significantly elevated when compared to the controls and smokers subjects as estimated by ANOVA.
#Significantly elevated compared to the group I subjects.
aSignificantly elevated when compared to controls and smokers experimental subject as estimated by ANOVA followed by Bonferroni’s correction for multiple comparisons.
Frequencies of comets scored in blood cells of tobacco users and controls.
| Subjects | Number of samples | Tail length (TL) (µM) mean ± SD) | Tail moment (TM) (mean ± SD) |
|---|---|---|---|
|
| 112 | 1.27 ± 1.06 | 1.12 ± 0.74 |
| Male | 39 | 1.10 ± 0.91 | 1.12 ± 0.80 |
| Female | 73 | 1.36 ± 1.13 | 1.12 ± 0.72 |
| | 156 | 1.64 ± 1.05 | 1.44 ± 1.15 |
| Male | 64 | 1.85 ± 1.11# | 1.78 ± 1.17a |
| Female | 92 | 1.48 ± 0.99 | 1.20 ± 1.09 |
|
| |||
| | 112 | 3.16 ± 1.36 | 2.62 ± 1.38 |
| Male | 39 | 3.46 ± 1.35 | 2.58 ± 1.61 |
| Female | 73 | 3.01 ± 1.35 | 2.64 ± 1.26 |
| | 156 | 4.31 ± 1.56* | 2.96 ± 1.41 |
| Male | 64 | 4.06 ± 1.63 | 3.07 ± 1.40 |
| Female | 92 | 4.48 ± 1.50# | 2.89 ± 1.41 |
|
| 268 | ||
| Smokers | 65 | 3.63 ± 1.54 | 2.72 ± 1.53 |
| SLT users | 154 | 3.71 ± 1.65 | 2.68 ± 1.25 |
| Smokers and SLT users | 49 | 4.48 ± 1.24** | 3.40 ± 1.58 |
*p < 0.001 level significantly elevated compared to controls groups.
#Significantly elevated when compared to controls and group I experimental male and female subject.
**Significantly elevated when compared to controls and smokers and SLT experimental subject as estimated by ANOVA followed by Bonferroni’s correction for multiple comparisons.